top of page
Incubate Survey: Early-Stage Biotech CEOs Warn Medicare's Pill Penalty Is Driving Capital Out of the Sector
Executives also cite NIH and FDA uncertainty, external reference pricing, tariffs, and research funding cuts as major threats WASHINGTON...
Incubate Coalition
May 8
Incubate Survey Finds That Drug Price Controls Create Headwinds for Life Sciences Startups
WASHINGTON ( January 13 ) -- Today, Incubate Policy Lab released insights from a survey of life sciences venture capital investors about...
Incubate Coalition
Jan 12
Incubate Launches Policy Lab Under New Leadership and Releases IP White Paper
Washington, DC, April 26, 2024 -- Today, on World Intellectual Property Day, Incubate is excited to launch Incubate Policy Lab under the...
Incubate Coalition
Apr 26, 2024
The Impact Of Price Controls On Investment Into Small Biotech Innovation
This report attempts to understand the implications of price controls on the early-stage life science industry. In the U.S., policymakers...
Incubate Coalition
Nov 11, 2021
SIGNAL WATCHING: How Life Science Venture Capital Perceives Medicare Part D Reforms
SIGNAL WATCHING: How Life Science Venture Capital Perceives Medicare Part D Reforms The 117th Congress is discussing a wide variety of...
Incubate Coalition
Sep 10, 2021
bottom of page